~~<i id='4E283AF313'><strike id='4E283AF313'><tt id='4E283AF313'><pre id='4E283AF313'></pre></tt></strike></i>~~

Home» explore» hotspot

hotspot

author：comprehensive 2025-09-28 11:38:01 Page View：27

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： STAT Madness 2024: Meet the contenders
Next article： Novavax promises a turnaround & Lilly roils the obesity market

leisure time

Medicare proposal to cover medical devices draws a mixed reaction

AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

Pfizer is about to make a big push in cancer. Will investors listen?

PfizerCEOAlbertBourlaGiannisPapanikos/APPfizerhasabigproblem.Thedruggianthopesthatnewdrugstotreatcan

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FILE-Abortion-rightsprotestersfillIndianaStatehousecorridorsandcheeroutsidelegislativechambers,Frida

Medicare Advantage isn’t working — for anyone

PabloMartinezMonsivais/APIn2023,enrollmentinMedicareAdvantage,theversionofMedicarerunbyprivateinsure